Capecitabine plus lapatinib combination is an effective chemotherapy regimen in patients with advanced breast cancer. Neurological adverse effects secondary to this regimen were reported rarely in literature. A woman with breast cancer presented with complaints of slurred speech while using the capecitabine and lapatinib combination. Her major complaint was slurred speech. No other radiologic or laboratory disorders were detected in the patient. Slurred speech improved one week after the capecitabine and lapatinib combination was discontinued without any further intervention.
CameronDCaseyMPressM. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat2008; 112: 533–543.
2.
GounarisIAhmadA. Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer. J Oncol Pharm Pract2010; 16: 277–279.
3.
TipplesKKolluriRRaoufS. Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion. J Oncol Pharm Pract2009; 15: 237–239.
4.
MukeshMMurrayP. Cerebellar toxicity with capecitabine in a patient with metastatic breast cancer. Clin Oncol (R Coll Radiol)2008; 20: 382–383.
SchullerJCassidyJDumontE. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol2000; 45: 291–297.
10.
KwonKAKwonHCKimMC. A case of 5-fluorouracil induced encephalopathy. Cancer Res Treat2010; 42: 118–120.
